Nephew uses ChatGPT during FOLFIRINOX; liver metastases regress

AI system

System: ChatGPT (an earlier model, later GPT-5)
Model: GPT-5 in the later phase.
Release: Exact release not established.
Application developer: OpenAI
Role: ChatGPT helped the author find and summarize relevant literature.
Configuration: The later phase used GPT-5. The earlier phase’s model is not identified in the existing account.
Inputs and outputs: Not assessed
Autonomy: Not assessed
Workflow: Family member with medical training prompting a general-purpose model for literature summaries. Standard FOLFIRINOX chemotherapy.
Human oversight: Not assessed
Relation to AI: ChatGPT's role, per the author, was literature navigation and summarization that shaped which supportive options the family considered. The author reports no efficacy claim and warns that outputs may be incorrect. The outcome is not attributable to the model.
AI contribution: ChatGPT's role, per the author, was literature navigation and summarization that shaped which supportive options the family considered. The author reports no efficacy claim and warns that outputs may be incorrect. The outcome is not attributable to the model.

Participants: Developer: OpenAI. Operator: The patient's nephew (Uzman Dent, Baku) with the patient.
Jurisdictions: Benefit: Baku, Azerbaijan (surgery and pathology performed in Turkey). Developer: United States.
Ownership and control: Not assessed
Dependencies: Not assessed
Cross-border connections: Not assessed
Geopolitical implications: Not assessed

Conditions for replication: Treating oncologists remain responsible for decisions. Model outputs verified against sources.
Replication attempts: Not assessed
Later findings: The single-author case report describes the clinical course through late 2025 and states that the contribution of the ChatGPT-guided adjuncts cannot be determined; no later development was found in the cited source.
Availability: Not assessed
Institutional decision: Not assessed
Grounds: Not assessed
Action and result: Not assessed
Success criterion: Not assessed

Assessed benefits: People. Organizations. Society.
Depth: Not assessed
Reasons: People: Complete radiological regression occurred on FOLFIRINOX. But the author states the case cannot determine the contribution of the model-informed adjuncts. Organizations: No organizational outcome. Society: Single case.
Observed or intended: Not assessed
Rubric: Not assessed
Assessor and date: Not assessed
Alternative assessments: Not assessed
Fill: The deployer's account

Kind: Not assessed
Related entries: Not assessed
Field: Health; oncology. Patients and families navigating cancer care.
Purpose: Patient-side literature navigation and summarization during cancer treatment
Dates: Date basis unassessed: 2026 (precision unassessed). Updated: 21 October 2026.
Stage: Not assessed
Version: SHA-256: 21651f0f623c…